Company Analysis

Search the recordZYBTCtrl K

Zhengye Biotechnology Holding Limited (ZYBT)

Nasdaq: ZYBT · Pharmaceutical Preparations · Jilin · filing with the SEC since 2023

Full chart Alerts Compare

Grade4.5

◀ Past 5.7● Present 5.0▶ Future 3.2

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

RevenueCN¥116M-37.6%

Net income-CN¥69.8M-717.0%

Earnings per sharen/a

Operating cash flowCN¥13.3M-67.5%

CashCN¥50.3M+170.5%

DebtCN¥9.6M-20.4%

Shareholders’ equityCN¥307M-13.0%

Shares, diluted47.3M+3.7%

Return on equity-22.8%

The recordfrom its filings

Filings in 202619

Newest filingNov 12 · 6-K

Annual reportApr 28, 2026

Quarterly reportn/a

Next report due20-F by Apr 30

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents grantedn/a

Filer categoryNon-accelerated filer<br>Emerging growth company

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

22232425

As filed, in CNY. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jul 21, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jun 25, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Jun 25, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Jun 25, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Jun 25, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Jun 25, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Jun 4, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Apr 28, 2026 · SEC EDGAR · Form 20-F

Annual report, foreign filer

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Zhengye Biotechnology Holding Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Jilin.

Newest on the record

Interim report, foreign filer on Nov 12. Before it, interim report, foreign filer on Aug 6.

What is due next

The 20-F for the period to Dec 31, 2026, due by Apr 30, 2027.

About ZYBT

Zhengye Biotechnology Holding Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Jilin. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of CNY 116 million and a loss of CNY 70 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersJilin

Business modelPre-revenue company

ExchangeNasdaq

Filing since2023

SEC number (CIK)1975641

Peers on fileLLY, KROS, CORT, UTHR

Financial performance

In fiscal 2025 Zhengye Biotechnology Holding’s revenue was CN¥116.4 million, down 37.6% from CN¥186.4 million the year before. It made a net loss of CN¥69.78 million.

Annual report, filed Apr 28, 2026.

Financial statements

The grade

Zhengye Biotechnology Holding grades 4.5 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past5.7

● Present5.0

▶ Future3.2

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ZYBT · research, not advice